Utility of skin testing in assessment of post-AZD1222 vaccine (AstraZeneca) allergic reactions: case series in Vietnam

Vu, Mai Thi; Nguyen, Anh Q.; Nguyen, Bo Duy; Duong, Huong Thu; Nguyen, Quyet Van; Nguyen, Ha H; Phung, Lam Nam; Nguyen, Dinh Van

doi:10.5415/apallergy.2021.11.e40

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A role for skin testing with mRNA vaccines in patients with previous allergic reaction to AZD1222 vaccine may also be noted. [20] To conclude, in the evaluation of the possibility for an allergic reaction from COVID-19 vaccines, sensitization via IDT, systemic reactions during skin testing regardless of sensitization and potentially the severity of the initial reaction may be of prognostic value. [17][18][19] History of anaphylaxis has been found to be associated with hypersensitivity reactions after a COVID-19 vaccine provocation test which was also conformed in our study.…”

Section: Discussionmentioning

confidence: 99%

Allergic Reactions With Skin Prick Test and Intradermal Test From the Anti Covid 19 Vaccines at Patients With High Risk for Hypersensitivity Our Experience

Svarca,

Bojadzieva,

Rashiti

et al. 2024

JMS

View full text Add to dashboard Cite

Introduction: Vaccines are recognized as one of the most effective public health interventions. Routine immunization has resulted in large reductions in vaccine-preventable disease and death. Vaccine-related hypersensitivity reactions are not uncommon. The concern about the occurrence of hypersensitivity reactions to the vaccine itself or to any component of the vaccine is one of the key obstacles to vaccination. Although this is an uncommon occurrence, it is necessary to establish a reliable approach in order to identify people who are at risk of such suffering. The rapid development and launch of several new COVID-19 vaccines (mRNA and adenovirus vector) is a new experience of modern science. Patients who are considered to be at high risk for allergy and/or have had a previous allergic reaction to the COVID-19 vaccine are usually referred to an allergist for vaccine allergy testing.Aim: The aim of this study was to present the allergic reactions with Skin Prick Test and Intradermal Test from the anti Covid 19 vaccines (mRNA and adeno viral vector) at patients with a history of allergy to the first COVID-19 vaccine dose as well as patients with high risk of allergic reaction.Material and methods: The research was a retrospective cross-sectional study that was conducted between December 2020 and February 2023 at the Clinic for Allergology and Clinical Immunology at the University Clinical Center in Kosovo,. The research included all patients aged ≥ 18 years who underwent a test for allergy to the vaccine against COVID-19, namely mRNA (BNT162b2, Pfizer) and/or adeno virus vector (AZD1222, AstraZeneca).Testing for allergy to the vaccine against COVID-19 was done by trained allergists, by applying IDT (intradermal test) or SPT (skin prick test). The study included all patients with an indication for testing for allergy to the Covid-19 vaccine due to a history of hypersensitivity to the first dose of the COVID-19 vaccine and/or due to a high risk of allergic reaction, including a history of atopic allergy or anaphylaxis.Results: SPT and IDT testing for allergic reactions from the mRNA vaccine (BNT162b2, Pfizer) indicated a positive finding in 4 (2.58%) of the patients. All positive findings were obtained from IDT testing. In 1 (0.64%) of the patients there was an IDT (1/100), and in 3 (3.80%) there were IDT (1/10) erythema and papules positive findings.Testing with SPT and IDT for allergic reactions from the vaccine AZD1222, Astra Zeneca indicated that there was a positive finding in 3 (3.80%) of the patients. All positive findings were obtained from IDT testing. One (1.26%) of the patients had IDT (1/100), and 2 (2.53%) had both IDT (1/100) and IDT (1/10) erythema and papulle positive findings.Conclusion: Our data support that cutaneous reactions to COVID-19 vaccination are generally minor and self-limited and should not discourage vaccination. Findings of the effect of SPT and IDT testing in the prediction of allergic reactions from the COVID-19 vaccines, as mRNA (BNT162b2, Pfizer) or adenovirus vector (AZD1222, As...

show abstract

Section: Discussionmentioning

confidence: 99%

Allergic Reactions With Skin Prick Test and Intradermal Test From the Anti Covid 19 Vaccines at Patients With High Risk for Hypersensitivity Our Experience

Svarca,

Bojadzieva,

Rashiti

et al. 2024

JMS

View full text Add to dashboard Cite

show abstract

“…In our case the effects of dermal atrophy are amplified by intradermal injection of the drug, even if diluted. There is growing evidence that skin tests with PEG excipients and polysorbate play an increasingly limited role in identifying those at risk of developing hypersensitivity reactions to vaccines for COVID-19, with a positive and negative predictive value yet to be established [7,19,20]. Other hypothesis likewise emerge that immediate hypersensitivity reactions can be determined not only by PEG and polysorbates but also by the lipid nanoparticles that build up the envelope of vaccines to mRNA and the mRNA itself [21].…”

Section: F O R P U B L I C a T I O Nmentioning

confidence: 99%

Skin atrophy after diagnostic tests with corticosteroids for the diagnosis of SARS-CoV-2 vaccine excipients hypersensitivity

Fabbri

Ortolani

Caron

et al. 2023

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

To the Editor, in December 2020 the SARS-CoV-2 vaccination campaign got started and several adverse reactions rapidly were reported, including suspected mild and anaphylactic allergic reactions. Nonanaphylactic allergic type reactions showed an incidence of 11.6 -43.8% cases per million first doses administered, however, anaphylactic reactions showed an incidence of 2.5 -11.1% cases per million first doses administered [1,2]. Right in the early stages of the worldwide SARS-CoV-2 vaccination campaign, vaccine excipients were hypothesized to be the culprits of the hypersensitivity reactions reported [3,4,5,6]. The SARS-CoV-2 excipients of the vaccines available in Italy, indicated as potential allergens, are shown in Table 1.

show abstract

Azd-1222

2023

Reactions Weekly

View full text Add to dashboard Cite

Utility of skin testing in assessment of post-AZD1222 vaccine (AstraZeneca) allergic reactions: case series in Vietnam

Cited by 4 publications

References 7 publications

Allergic Reactions With Skin Prick Test and Intradermal Test From the Anti Covid 19 Vaccines at Patients With High Risk for Hypersensitivity Our Experience

Allergic Reactions With Skin Prick Test and Intradermal Test From the Anti Covid 19 Vaccines at Patients With High Risk for Hypersensitivity Our Experience

Skin atrophy after diagnostic tests with corticosteroids for the diagnosis of SARS-CoV-2 vaccine excipients hypersensitivity

Azd-1222

Contact Info

Product

Resources

About